Interstitial lung disease: We identified an indirect effect of SGLT2 inhibition on interstitial lung disease through the family Enterobacteriaceae id.3469 (OR: 0.499, 95% CI: 0.396–0.629, P = 3.71×10-9), and the order Enterobacteriales id.3468(OR: 0.499, 95% CI: 0.396–0.629, P = 3.71×10-9), with a mediated proportion of 10.87% (95% CI: 0.079–0.138, P = 2.08×10-4) and 10.87% (95% CI: 0.079–0.138, P = 2.08×10-4) of the total effect. Here, SLC5A2 is linked to interstitial lung disease.